Page web : https://ecolesdoctorales.parisdescartes.fr/ed436_eng/Research-Units/Team-composition/Central-Neuropeptides-and-regulations-of-body-fluid-homeostasis-and-cardiovascular-functions.
1Leenen F.H.H., Ahmad M., Marc Y. et Llorens-Cortes C., « Specific inhibition of brain angiotensin III formation as a new strategy for prevention of heart failure after myocardial infarction », J Cardiovasc Pharmacol., vol. 73, no 2, 2019, p. 82-91, https://doi.org/10.1097/fjc.0000000000000638 [PMID : 30531435].
Boitard S.E., Marc Y., Keck M., Mougenot N., Agbulut O., Balavoine F. et Llorens-Cortes C., « Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice », J Mol Cell Cardiol., vol. 127, 2019, p. 215-222, https://doi.org/10.1016/j.yjmcc.2018.12.008 [PMID : 30599150].
Fischer C., Lamer T., Wang W., McKinnie S.M.K., Iturrioz X., Llorens-Cortes C., Oudit G.Y. et Vederas J.C., « Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents », Eur J Med Chem., vol. 166, 2019, vol. 119-124, https://doi.org/10.1016/j.ejmech.2019.01.040 [PMID : 30690406].
Keck M., Hmazzou R. et Llorens-Cortes C., « Orally Active Aminopeptidase A Inhibitor Prodrugs: Current state and future directions », Curr Hypertens Rep., vol. 21, no 7, 2019, art. 50, https://doi.org/10.1007/s11906-019-0957-4 [PMID : 31115779].
Keck M., De Almeida H., Compère D., Inguimbert N., Flahault A., Balavoine F., Roques B. et Llorens-Cortes C., « NI956/QGC006, a potent orally active, brain-penetrating aminopeptidase a inhibitor for treating hypertension », Hypertension, vol. 73, no 6, 2019, p. 1300-1307, https://doi.org/10.1161/HYPERTENSIONAHA.118.12499 [PMID : 3106719].
Arendse L.B., Danser A.H.J., Poglitsch M., Touyz R.M., Burnett J.C., Llorens-Cortes C., Ehlers M.R. et Sturrock E.D., « Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure », Pharmacological Reviews, vol. 71, no 4, 2019, p. 539-570, https://doi.org/10.1124/pr.118.017129.
Marsault E., Llorens-Cortes C., Iturrioz X., Chun H.J., Lesur O., Oudit G.Y. et Auger-Messier M., « The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders », Annals of the New York Academy of Sciences, vol. 1455, no 1, 2019, p. 12-33, https://doi.org/10.1111/nyas.14123.
Azizi M., Courand P.-Y., Denolle T., Delsart P., Zhygalina V., Amar L., Lantelme P., Mounier-Vehier C., de Mota N., Balavoine F. et Llorens-Cortes C., « A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension », Journal of Hypertension, vol. 37, no 8, 2019, p. 1722-1728, https://doi.org/10.1097/HJH.0000000000002092.
2Droctové L., Lancien M., Tran V.L., Susset M., Jego B., Theodoro F., Kessler P., Mourier G., Robin P., Diarra S.S., Palea S., Flahault A., Chorfa A., Corbani M., Llorens-Cortes C., Mouillac B., Mendre C., Pruvost A., Servent D., Truillet C. et Gilles N., « A snake toxin as a theranostic agent for the type 2 vasopressin receptor », Theranostics, vol. 10, 25, 2020, p. 11580-11594, https://doi.org/10.7150/thno.47485 [PMID : 33052234].